InvestSMART

MedAdvisor Limited (ASX:MDR)

ALERT: Price-sensitive ASX Announcement for MDR
Current share price for MDR : $0.022 -0.006 (-21.43%)+
Announcement
Release
22 Oct 2025 9:49AM
Price at Release
$0.028
Full Release
download
Summary
In the 1Q FY26 Quarterly Activity Report, MedAdvisor Limited (ASX: MDR) announced significant developments, including a 52.8% decrease in operating revenue compared to the prior year, with revenues down to $9.6 million and a gross profit of $4.1 million. This decline was partly due to U.S. government policy pressures and financial challenges within the pharmacy sector. The sale of the ANZ business to Jonas Software AUS was completed for $35 million, with additional earn-outs expected. The company reported a net cash position of $13 million after discharging all debts. Key strategic initiatives include the U.S. Transformation 360° program, which is 80% complete, and aims to reduce operating expenses by 15% in FY26. Despite ongoing market challenges, MedAdvisor focuses on leveraging AI to enhance patient engagement and drive new revenue streams, with a projected U.S. health program pipeline exceeding $100 million. The company's strategic priorities include completing the new patient engagement platform and expanding its digital reach within the pharmacy network.
Key Points
  • 1Q FY26 revenue decreased by 52.8% to $9.6 million.
  • Gross profit fell by 60.4% to $4.1 million.
  • Sale of ANZ business completed for $35 million.
  • Net cash position of $13 million after debt discharge.
  • U.S. Transformation 360° program 80% complete.
  • Expected reduction in operating expenses by 15% in FY26.
  • Projected U.S. health program pipeline over $100 million.
  • Focus on AI to enhance patient engagement and revenue.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.